NEUROCRINE BIOSCIENCES INC (NBIX)
US64125C1099 - Common Stock
Taking everything into account, NBIX scores 8 out of 10 in our fundamental rating. NBIX was compared to 588 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make NBIX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
NBIX had positive earnings in the past year.
NBIX had a positive operating cash flow in the past year.
Each year in the past 5 years NBIX has been profitable.
In the past 5 years NBIX always reported a positive cash flow from operatings.
1.2 Ratios
NBIX has a Return On Assets of 7.68%. This is amongst the best in the industry. NBIX outperforms 96.75% of its industry peers.
The Return On Equity of NBIX (11.19%) is better than 96.40% of its industry peers.
With an excellent Return On Invested Capital value of 11.21%, NBIX belongs to the best of the industry, outperforming 96.92% of the companies in the same industry.
NBIX had an Average Return On Invested Capital over the past 3 years of 9.89%. This is below the industry average of 13.58%.
The 3 year average ROIC (9.89%) for NBIX is below the current ROIC(11.21%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.68% | ||
| ROE | 11.19% | ||
| ROIC | 11.21% |
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
1.3 Margins
With an excellent Profit Margin value of 13.23%, NBIX belongs to the best of the industry, outperforming 96.92% of the companies in the same industry.
NBIX's Profit Margin has improved in the last couple of years.
NBIX has a better Operating Margin (20.92%) than 97.09% of its industry peers.
In the last couple of years the Operating Margin of NBIX has grown nicely.
The Gross Margin of NBIX (97.90%) is better than 98.29% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.92% | ||
| PM (TTM) | 13.23% | ||
| GM | 97.9% |
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NBIX is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
NBIX has more shares outstanding than it did 5 years ago.
NBIX has a better debt/assets ratio than last year.
2.2 Solvency
NBIX has an Altman-Z score of 9.56. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
NBIX has a Altman-Z score of 9.56. This is amongst the best in the industry. NBIX outperforms 86.13% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.47 | ||
| Altman-Z | 9.56 |
ROIC/WACC1.22
WACC9.16%
2.3 Liquidity
NBIX has a Current Ratio of 2.45. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NBIX (2.45) is worse than 73.63% of its industry peers.
NBIX has a Quick Ratio of 2.40. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX's Quick ratio of 2.40 is on the low side compared to the rest of the industry. NBIX is outperformed by 72.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.4 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.17%, which is quite impressive.
The Earnings Per Share has been growing by 70.09% on average over the past years. This is a very strong growth
The Revenue has grown by 26.76% in the past year. This is a very strong growth!
The Revenue has been growing by 33.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.17%
EPS 3Y23.01%
EPS 5Y70.09%
EPS growth Q2Q63.64%
Revenue 1Y (TTM)26.76%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Revenue growth Q2Q25.05%
3.2 Future
Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 42.64% on average per year.
NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.87% yearly.
EPS Next Y101.21%
EPS Next 2Y63.13%
EPS Next 3Y52.9%
EPS Next 5Y42.64%
Revenue Next Year17.23%
Revenue Next 2Y16.74%
Revenue Next 3Y15.46%
Revenue Next 5Y13.87%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 57.43, the valuation of NBIX can be described as expensive.
NBIX's Price/Earnings ratio is rather cheap when compared to the industry. NBIX is cheaper than 95.03% of the companies in the same industry.
NBIX is valuated expensively when we compare the Price/Earnings ratio to 25.25, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 28.54, which means the current valuation is very expensive for NBIX.
Based on the Price/Forward Earnings ratio, NBIX is valued cheaply inside the industry as 95.55% of the companies are valued more expensively.
NBIX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.67, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.43 | ||
| Fwd PE | 28.54 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 95.21% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaper than 95.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.65 | ||
| EV/EBITDA | 28.04 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 52.90% in the coming years.
PEG (NY)0.57
PEG (5Y)0.82
EPS Next 2Y63.13%
EPS Next 3Y52.9%
5. Dividend
5.1 Amount
No dividends for NBIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (4/24/2024, 4:34:37 PM)
After market: 138.97 0 (0%)138.97
-1.12 (-0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.98B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.43 | ||
| Fwd PE | 28.54 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.57
PEG (5Y)0.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.68% | ||
| ROE | 11.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 20.92% | ||
| PM (TTM) | 13.23% | ||
| GM | 97.9% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.17%
EPS 3Y23.01%
EPS 5Y
EPS growth Q2Q
EPS Next Y101.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.76%
Revenue growth 3Y21.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y